STAT

A trip to ‘the poopy lab’ in the interest of drug development

A University of Guelph scientist uses a mechanical colon she calls the "Robogut" to study the gut microbiome and produce "feces" for a clinical trial to treat C. difficile infections.

GUELPH, Ontario — Outside of Emma Allen-Vercoe’s office is a bulletin board pinned with her team’s scientific papers since 2013. It’s the academic’s answer to a military uniform grown heavy with medals.

But all of that research has come with a side effect: an impressive intimacy with the smells of human digestion.

“This is what we formally call the poopy lab,” she said one morning at the end of January. “Every donor that we use has a distinct aroma, because they have a different profile of microbes in the gut, so it’s like a fine wine — just not quite so fine. I guess this is Eau de Ulcerative Colitis … which smells different from

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks